DuoResp® Spiromax® adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT)

Job van der Palen, Isa Cerveri, Nicolas Roche, Dave Singh, Vicente Plaza, Chelo Gonzalez, Oliver Patino, Irma Scheepstra, Guilherme Safioti, Vibeke Backer

Research output: Contribution to journalArticle

Abstract

Objective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp® Spiromax® among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. DuoResp Spiromax users self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8®), and ease of use and satisfaction using 10-point scales, during a single physician’s office visit. Results: Of 1661 (asthma: n = 1101; COPD: n = 560) SPRINT study participants, 342 (asthma: n = 235; COPD: n = 107) received DuoResp Spiromax prior to inclusion. Overall, 72.5% of DuoResp Spiromax users reported medium or high adherence (MMAS-8 score ≥6). Mean (standard deviation [SD]) satisfaction score for DuoResp Spiromax was 8.9 (1.6). Almost all (98.8%) DuoResp Spiromax users were at least satisfied with their inhaler; 85.4% were very satisfied. Mean (SD) ease of use score for DuoResp Spiromax was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use.

Original languageEnglish
JournalJournal of Asthma
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Observational Studies
Asthma
Medication Adherence
Office Visits
Physicians' Offices
Adrenal Cortex Hormones

Keywords

  • adherence
  • Asthma
  • COPD
  • DuoResp Spiromax
  • ICS/LABA
  • satisfaction

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

DuoResp® Spiromax® adherence, satisfaction and ease of use : findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). / van der Palen, Job; Cerveri, Isa; Roche, Nicolas; Singh, Dave; Plaza, Vicente; Gonzalez, Chelo; Patino, Oliver; Scheepstra, Irma; Safioti, Guilherme; Backer, Vibeke.

In: Journal of Asthma, 01.01.2019.

Research output: Contribution to journalArticle

van der Palen, Job ; Cerveri, Isa ; Roche, Nicolas ; Singh, Dave ; Plaza, Vicente ; Gonzalez, Chelo ; Patino, Oliver ; Scheepstra, Irma ; Safioti, Guilherme ; Backer, Vibeke. / DuoResp® Spiromax® adherence, satisfaction and ease of use : findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). In: Journal of Asthma. 2019.
@article{77e824bcf21248d49b0f7cb487a3c215,
title = "DuoResp{\circledR} Spiromax{\circledR} adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT)",
abstract = "Objective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp{\circledR} Spiromax{\circledR} among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. DuoResp Spiromax users self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8{\circledR}), and ease of use and satisfaction using 10-point scales, during a single physician’s office visit. Results: Of 1661 (asthma: n = 1101; COPD: n = 560) SPRINT study participants, 342 (asthma: n = 235; COPD: n = 107) received DuoResp Spiromax prior to inclusion. Overall, 72.5{\%} of DuoResp Spiromax users reported medium or high adherence (MMAS-8 score ≥6). Mean (standard deviation [SD]) satisfaction score for DuoResp Spiromax was 8.9 (1.6). Almost all (98.8{\%}) DuoResp Spiromax users were at least satisfied with their inhaler; 85.4{\%} were very satisfied. Mean (SD) ease of use score for DuoResp Spiromax was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use.",
keywords = "adherence, Asthma, COPD, DuoResp Spiromax, ICS/LABA, satisfaction",
author = "{van der Palen}, Job and Isa Cerveri and Nicolas Roche and Dave Singh and Vicente Plaza and Chelo Gonzalez and Oliver Patino and Irma Scheepstra and Guilherme Safioti and Vibeke Backer",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/02770903.2019.1634097",
language = "English",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - DuoResp® Spiromax® adherence, satisfaction and ease of use

T2 - findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT)

AU - van der Palen, Job

AU - Cerveri, Isa

AU - Roche, Nicolas

AU - Singh, Dave

AU - Plaza, Vicente

AU - Gonzalez, Chelo

AU - Patino, Oliver

AU - Scheepstra, Irma

AU - Safioti, Guilherme

AU - Backer, Vibeke

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp® Spiromax® among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. DuoResp Spiromax users self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8®), and ease of use and satisfaction using 10-point scales, during a single physician’s office visit. Results: Of 1661 (asthma: n = 1101; COPD: n = 560) SPRINT study participants, 342 (asthma: n = 235; COPD: n = 107) received DuoResp Spiromax prior to inclusion. Overall, 72.5% of DuoResp Spiromax users reported medium or high adherence (MMAS-8 score ≥6). Mean (standard deviation [SD]) satisfaction score for DuoResp Spiromax was 8.9 (1.6). Almost all (98.8%) DuoResp Spiromax users were at least satisfied with their inhaler; 85.4% were very satisfied. Mean (SD) ease of use score for DuoResp Spiromax was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use.

AB - Objective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp® Spiromax® among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. DuoResp Spiromax users self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8®), and ease of use and satisfaction using 10-point scales, during a single physician’s office visit. Results: Of 1661 (asthma: n = 1101; COPD: n = 560) SPRINT study participants, 342 (asthma: n = 235; COPD: n = 107) received DuoResp Spiromax prior to inclusion. Overall, 72.5% of DuoResp Spiromax users reported medium or high adherence (MMAS-8 score ≥6). Mean (standard deviation [SD]) satisfaction score for DuoResp Spiromax was 8.9 (1.6). Almost all (98.8%) DuoResp Spiromax users were at least satisfied with their inhaler; 85.4% were very satisfied. Mean (SD) ease of use score for DuoResp Spiromax was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use.

KW - adherence

KW - Asthma

KW - COPD

KW - DuoResp Spiromax

KW - ICS/LABA

KW - satisfaction

UR - http://www.scopus.com/inward/record.url?scp=85068764008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068764008&partnerID=8YFLogxK

U2 - 10.1080/02770903.2019.1634097

DO - 10.1080/02770903.2019.1634097

M3 - Article

AN - SCOPUS:85068764008

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

ER -